Isis Innovation Limited

Oxford University Innovation Limited

Glaxosmithkline Biologicals Sa

Adrian Vivian Hill

Simon Draper

Sarah C Gilbert

Arturo Reyes

Alexander Douglas

Saranya Sridhar

Anna Goodman

Andrew Williams

Joseph Illingworth

Stefano Colloca

Riccardo Cortese

Andrew James McMichael

Matthew Guy Cottingham

Ansar Pathan

Derek Parry Jewell

Frances M Gotch

Helen McShane

Hilton Carter Whittle

John Elvin

Geraldine O'Hara

Anne Moore

Robert Paul Anderson

Matthew Douglas Dicks

Ansar A Pathan

An adenoviral vector comprising a promoter further comprising a fragment of the 5' untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumor antigen for use as a medicament.

Adenovirus vectors

The invention provides recombinant adenoviral vectors which are capable of eliciting immunity against the pre-erythrocytic stage of the life cycle of the malaria parasite. In particular, the invention provides a recombinant, replication deficient simian adenoviral vector which encodes an antigen comprising the thrombospondin-related adhesion protein (TRAP), and also immunogenic compositions (e.g. vaccines) comprising the vector and methods of using such compositions.

Simian adenoviral vectors encoding malaria antigen

There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector that expresses PfRH5 antigen having at least 90% identity with SEQ ID NO: 2, or a fragment thereof.

Treatment and prevention of malaria

A method for generating a T cell immune response in a host involving administering a vectored vaccine comprising a non-replicating or replication impaired viral vector expressing the translation product of a mycobacterial antigen 85A gene. Vectored vaccines and uses thereof are also provided. Also provided is a method of inducing a CD8 and a CD4 memory T cell response against an antigen using an adenovirus vector expressing an antigen or an immunogenic fragment thereof.

Compositions for immunizing against mycobacterium

Plasmodium falciparum MHC class I-restricted CTL epitopes derived from

The present application is drawn to HLA type and sub-type specific oligonucleotides and their methods of use.

Process for amplifying nucleic acid

Process for amplifying HLA sequences

Growing community of inventors

Oxford, United Kingdom

Adrian Vivian Hill